Skip to main content
Clinical Trials/NCT03950531
NCT03950531
Completed
Not Applicable

The Effect of Bronchiectasis on the Exacerbation and Mortality of Chronic Obstructive Pulmonary Disease

Ministry of Health, Turkey0 sites122 target enrollmentJanuary 25, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchiectasis
Sponsor
Ministry of Health, Turkey
Enrollment
122
Primary Endpoint
Charlson Comorbidity Index
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways and lungs that develops against harmful particles or gases with exacerbations. Coexistence of bronchiectasis with COPD may lead to worsening of the functional parameters as well as alteration of the microbiological pattern in exacerbations and may negatively affect the exacerbation result parameters.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways and lungs that develops against harmful particles or gases with exacerbations. COPD exacerbations are characterized by worsening of dyspnea, coughing and expectoration. Exacerbations requiring hospitalization are the main cause of morbidity and mortality in COPD. Bronchiectasis is the irreversible extension of the bronchi. Usually follows with chronic sputum cough, airway obstruction and recurrent infection episodes. The association of bronchiectasis and COPD has long been known and its incidence is in the range of 30-50%. Coexistence of bronchiectasis with COPD may lead to worsening of the functional parameters as well as alteration of the microbiological pattern in exacerbations and may negatively affect the exacerbation result parameters.

Registry
clinicaltrials.gov
Start Date
January 25, 2010
End Date
January 25, 2017
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ministry of Health, Turkey
Responsible Party
Principal Investigator
Principal Investigator

Zeynep FENDOGLU

Principal investigator

Ministry of Health, Turkey

Eligibility Criteria

Inclusion Criteria

  • Patients who underwent thoracic tomography in the last year according to index exacerbation date were included in the study

Exclusion Criteria

  • Cases that mimic COPD exacerbation (pneumonia, pulmonary thromboembolism, pulmonary congestion, pneumothorax, pleural effusion, lung malignancy, asthma, asthma-COPD overlap syndrome) and patients admitted to the intensive care unit were excluded from the study.

Outcomes

Primary Outcomes

Charlson Comorbidity Index

Time Frame: 1 hour

Comorbidity scores

Secondary Outcomes

  • Spirometry(1 hour)

Similar Trials